The present study shows that mutations in the ALPL and CYP1A1 genes may be related to the development of AFF in patients receiving BPs indicating the need to evaluate ALP substrates in patients with low total ALP levels prior to initiating BP treatment. The gene discussed is ALPL; the disease is Bartsocas-Papas syndrome 1.